Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsAntonio Omuro, MD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Biography
Dr. Omuro is a Professor Adjunct in the department of Neurology at the Yale School of Medicine.
He is the former chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers.
Dr. Omuro is currently the chair of the Department of Neurology and Neurological Sciences at Stanford University.
Last Updated on July 15, 2024.
Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2004)
- MD
- Sao Paulo School of Medicine (1995)
Research
Copy Link
Overview
Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.
Medical Research Interests
Central Nervous System Neoplasms; Clinical Trial; Glioblastoma; Meningeal Neoplasms
ORCID
0000-0003-4299-3664
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonio Omuro's published research.
Publications Timeline
A big-picture view of Antonio Omuro's research output by year.
Research Interests
Research topics Antonio Omuro is interested in exploring.
Sanjay Aneja, MD
MingDe Lin, PhD
Veronica Chiang, MD, FAANS
Tal Zeevi
Alexandria Brackett, MLIS, AHIP, MA
David A. Hafler, MD, FANA
271Publications
24,391Citations
Central Nervous System Neoplasms
Glioblastoma
Meningeal Neoplasms
Publications
2025
CTNI-39. TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
Nayak L, Grommes C, Kallam A, Peereboom D, Ambady P, Mendez J, Aregawi D, Sumrall A, Omuro A, Iwamoto F, Dietrich J, Umemura Y, Munker R, Chukwueke U, Schaff L, Prados S, Takazawa A, Aoi A, Batchelor T. CTNI-39. TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY. Neuro-Oncology 2025, 27: v135-v135. PMCID: PMC12601121, DOI: 10.1093/neuonc/noaf201.0535.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaDuration of responseProgression-free survivalOverall response rateTreatment-emergent adverse eventsCentral nervous system lymphomaNervous system lymphomaSystem lymphomaData cutoffOverall survivalResponse rateProspective studyTreatment optionsRefractory primary central nervous system lymphomaSecond-generation Bruton's tyrosine kinase inhibitorOpen-label phase II studyMedian duration of responsePhase II prospective studyRare non-Hodgkin lymphomaBruton tyrosine kinase inhibitorComplete response ratePartial response rateMaculo-papular rashNon-Hodgkin's lymphomaPhase II studyMulticenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma
Omuro A, DeAngelis L, Polley M, Correa D, Wefel J, Bovi J, Rosenblum M, Corn B, Aneja S, Grommes C, Peereboom D, Lallana E, Werner-Wasik M, Rogers C, Iwamoto F, Yu H, Donnelly E, Struve T, Won M, Mehta M. Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma. Neuro-Oncology 2025, noaf221. PMID: 41189315, DOI: 10.1093/neuonc/noaf221.Peer-Reviewed Original ResearchAltmetricConceptsPrimary central nervous system lymphomaProgression-free survivalMulticenter randomized phase II studyWhole-brain radiotherapyOverall survivalIntent-to-treatHazard ratioDose of whole-brain radiotherapyRisk of severe neurotoxicityCentral nervous system lymphomaLow radiotherapy dosesPrimary CNS lymphomaNervous system lymphomaSingle-arm studyDisease controlCNS lymphomaRadiotherapy doseSystem lymphomaPrimary endpointMedian ageChemoRTLow-doseSevere neurotoxicityFollow-upResponse ratePhase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas
Schiff D, Ye X, Li J, Ellingson B, Wen P, Walbert T, Campian J, Nabors L, Ozer B, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra R. Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas. Neuro-Oncology 2025, noaf246. PMID: 41099363, DOI: 10.1093/neuonc/noaf246.Peer-Reviewed Original ResearchAltmetricConceptsWindow-of-opportunity studyProgression-free survivalIDH mutant gliomasMutant gliomasPARP inhibitorsIntratumoral pharmacokineticsMedian progression-free survivalProlonged progression-free survivalArm B patientsCumulative hematologic toxicityLow-dose temozolomidePhase II doseActivity of PARP inhibitorsLong-term tolerancePharmacologically active concentrationsNon-enhancing tumorDaily temozolomideII doseMetronomic temozolomideRANO criteriaHematologic toxicityRadiographic responseRecurrent gliomaPartial responseArm AOS04.6.A MULTICENTER RANDOMIZED PHASE II STUDY OF R-MPV-A CHEMOIMMUNOTHERAPY WITH OR WITHOUT LOW-DOSE WHOLE-BRAIN RADIOTHERAPY FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: NRG/ RTOG 1114
Omuro A, Deangelis L, Polley M, Correa D, Wefel J, Bovi J, Rosenblum M, Corn B, Aneja S, Grommes C, Peereboom D, Lallana E, Werner-Wasik M, Rogers C, Iwamoto F, Yu H, Donnelly E, Struve T, Won M, Mehta M. OS04.6.A MULTICENTER RANDOMIZED PHASE II STUDY OF R-MPV-A CHEMOIMMUNOTHERAPY WITH OR WITHOUT LOW-DOSE WHOLE-BRAIN RADIOTHERAPY FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: NRG/ RTOG 1114. Neuro-Oncology 2025, 27: iii15-iii16. PMCID: PMC12493833, DOI: 10.1093/neuonc/noaf193.045.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaProgression-free survivalOverall survivalIntent-to-treatPrimary endpointDose of whole-brain radiotherapyNewly diagnosed primary CNS lymphomaHazard ratioDiagnosed primary CNS lymphomaRisk of severe neurotoxicityCentral nervous system lymphomaLow radiotherapy dosesPrimary CNS lymphomaWhole-brain radiotherapyComplete response rateNervous system lymphomaSingle-arm studyCNS lymphomaRadiotherapy doseSystem lymphomaChemotherapy regimenSalvage treatmentMethotrexate doseMedian ageChemoRT88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
Nayak L, Grommes C, Kallam A, Peereboom D, Ambady P, Mendez J, Aregawi D, Sumrall A, Omuro A, Iwamoto F, Dietrich J, Umemura Y, Munker R, Chukwueke U, Schaff L, Prados S, Takazawa A, Aoi A, Batchelor T. 88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY. Hematological Oncology 2025, 43 DOI: 10.1002/hon.70093_88.Peer-Reviewed Original ResearchTirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
Nayak L, Grommes C, Kallam A, Peereboom D, Ambady P, Mendez J, Aregawi D, Sumrall A, Omuro A, Iwamoto F, Dietrich J, Umemura Y, Munker R, Chukwueke U, Schaff L, Prados S, Takazawa A, Aoi A, Batchelor T. Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study. Journal Of Clinical Oncology 2025, 43: 2019-2019. DOI: 10.1200/jco.2025.43.16_suppl.2019.Peer-Reviewed Original ResearchCitationsConceptsPrimary central nervous system lymphomaTreatment-emergent adverse eventsTreatment-related adverse eventsDuration of responseProgression-free survivalTime to responseMedian duration of responseCentral nervous system lymphomaNervous system lymphomaTyrosine kinase inhibitorsSystem lymphomaOverall survivalResponse rateNeutrophil countProspective studyAdverse eventsTreatment optionsRefractory primary central nervous system lymphomaSecond-generation Bruton's tyrosine kinase inhibitorAggressive form of non-Hodgkin lymphomaOpen-label phase II studyDisease progressionMedian progression-free survivalPhase II prospective studyMedian time to response
2024
NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchConceptsGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancementJS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martínez-García M, Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2024, 26: v13-v13. PMCID: PMC11485993, DOI: 10.1093/neuonc/noae144.036.Peer-Reviewed Original ResearchConceptsNon-contrast-enhancedMouse double minute 2Contrast enhancementMGMT promoter unmethylated glioblastomaPatient-derived xenograft modelsUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMMaximum tolerated doseNewly diagnosed glioblastomaTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsDouble minute 2Restore wild-typeBrain tissueBrain tumor tissueTP53 WTUnmethylated glioblastomaPhase 0Diagnosed glioblastomaTolerated doseOpen-labelP53 target gene expressionIDH-wtA phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martinez-Garcia M, Sepulveda Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2024, 42: 2017-2017. DOI: 10.1200/jco.2024.42.16_suppl.2017.Peer-Reviewed Original ResearchCitationsConceptsNon-contrast-enhancedOpen-labelContrast enhancementMGMT promoter unmethylated glioblastomaUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMDose-escalation studyMaximum tolerated doseTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsRestore wild-typeBrain tissueUnmethylated glioblastomaBrain tumor tissueEscalation studyDiagnosed glioblastomaTolerated doseP53 target gene expressionPrimary endpointIDH-wtSolid tumorsTumor tissuesXenograft modelRadiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, Chenevert T, Michalski J, Gilbert M, Le Q, Omuro A, Men K, Aldape K, Cao Y, Srinivasan A, Barani I, Sachdev S, Huang J, Choi S, Shi W, Battiste J, Wardak Z, Chan M, Mehta M, Xiao Y. Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach. Cancers 2024, 16: 2007. PMID: 38893130, PMCID: PMC11171017, DOI: 10.3390/cancers16112007.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIntensity-modulated proton therapyPlan quality assuranceOrgan-at-riskRT planningQuality of radiation therapyClinical trialsIMPT plansKBP modelPlan QAPhoton plansRadiation therapyPhoton modelKBP plansTarget coveragePlan qualityProton therapyNasopharyngeal carcinomaMulti-institutional clinical trialsNRG Oncology trialsProton modelOutcomes of clinical trialsMulti-center clinical trialPhoton RTQuality assuranceHead/neck cancer
News
Copy Link
Get In Touch
Copy Link